tutorial

Inflammatory Myofibroblastic Tumor Care Tech Platform Monitoring Guide 2026

"A comprehensive guide to monitoring digital health platforms supporting inflammatory myofibroblastic tumor (IMT) care, covering ALK and fusion gene molecular routing, crizotinib and next-generation ALK inhibitor adherence, pediatric and young adult care coordination, rare tumor registry enrollment, and multi-center surgical and recurrence surveillance workflows."

Inflammatory Myofibroblastic Tumor Care Tech Platform Monitoring Guide 2026

Overview

Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm of intermediate biologic behavior, classified by the WHO as a locally aggressive, rarely metastasizing tumor with a propensity for local recurrence. IMT occurs across a broad age range but is disproportionately common in children, adolescents, and young adults, with a median age at diagnosis in the second to fourth decade of life. Anatomically, IMT arises most commonly in the lung, mesentery, retroperitoneum, pelvis, and soft tissues of the extremities, though nearly any body site has been reported. The histologic hallmark is a proliferation of spindled myofibroblastic cells embedded in a variably inflammatory stroma containing lymphocytes, plasma cells, and eosinophils — a morphology that can mimic inflammatory fibrosarcoma or other spindle cell neoplasms.

The most defining molecular feature of IMT is the presence of kinase gene fusions, present in approximately 50–60% of cases. ALK fusions are the most common — typically ALK-TPM3, ALK-TPM4, ALK-CLTC, or ALK-ATIC — and are detectable by ALK IHC (a sensitive screening tool) with confirmation by fluorescence in situ hybridization (FISH) or RNA fusion sequencing. Non-ALK fusion partners identified in ALK IHC-negative IMT include ROS1 (ROS1-PPFIBP1, ROS1-TFG), NTRK1/3 (LMNA-NTRK1), RET, PDGFR-beta, and HMGA2 rearrangements — each with implications for targeted therapy eligibility under the relevant histology-agnostic approvals or early-phase trials.

The clinical management of IMT is surgical when resection with negative margins is achievable. ALK-positive unresectable or recurrent IMT responds dramatically to ALK inhibitors: crizotinib demonstrated response rates of 60–80% in ALK-positive IMT in early series, and next-generation ALK inhibitors (alectinib, lorlatinib, ceritinib) are increasingly used for crizotinib-resistant or CNS-metastatic disease. ROS1 fusions are targetable with entrectinib or crizotinib; NTRK fusions are targetable with larotrectinib or entrectinib under histology-agnostic FDA approvals. Given its rarity, IMT is a prototype tumor for care technology platforms that must support molecular reflex testing, targeted therapy CDS, rare tumor registry enrollment, multi-center care coordination, and long-term recurrence surveillance.

Care Technology Landscape

ALK and Fusion Gene Molecular Testing Platforms — IMT diagnosis triggers a molecular workup: ALK IHC as first-line screen, with ALK FISH or RNA fusion panel (preferably comprehensive RNA sequencing) to confirm and characterize the specific fusion partner. In ALK IHC-negative cases, comprehensive RNA-based fusion sequencing is essential to detect ROS1, NTRK, RET, PDGFR-beta, and other non-ALK rearrangements. Laboratory information systems must support the reflex logic from ALK IHC to confirmatory testing, and must route structured fusion results to both the oncology information system and clinical trial eligibility engines.

Targeted Therapy CDS and Eligibility Platforms — Given the multiple targetable fusion types and the evolving landscape of histology-agnostic approvals, CDS systems supporting IMT must fire for: ALK fusion (crizotinib, alectinib, lorlatinib), ROS1 fusion (entrectinib, crizotinib), NTRK1/2/3 fusion (larotrectinib, entrectinib under TRK inhibitor approval), RET fusion (selpercatinib, pralsetinib under RET approval), and PDGFR-beta (imatinib). CDS must also generate clinical trial eligibility notifications for IMT-specific or sarcoma-basket protocols active at the treating institution.

Rare Tumor Registry and Multi-Center Coordination Systems — IMT is rare enough that most centers manage fewer than 5–10 cases per year. Registry enrollment platforms must identify newly diagnosed IMT cases from pathology sign-out, enroll them in institutional and cooperative group registries (e.g., COG ARST protocols, the NCI MATCH sarcoma arm, or international sarcoma registries), and transmit structured molecular and clinical data to registry repositories. Multi-center care coordination platforms must support secure transfer of imaging, pathology reports, and molecular data to high-volume sarcoma or pediatric oncology referral centers.

Pediatric and Young Adult Care Coordination Systems — Because IMT disproportionately affects patients under 25, care coordination platforms must interface with pediatric oncology teams, pediatric surgery, and — for young adults transitioning from pediatric care — adolescent and young adult (AYA) oncology programs. Fertility preservation consultation workflows, school and work accommodation systems, and psychosocial support referral pathways are all relevant care technology components for this population.

Recurrence and Surveillance Imaging Platforms — IMT recurs locally in 25–40% of cases even after margin-negative resection. Surveillance imaging schedules (CT or MRI of the primary site every 3–6 months for 2–3 years, then annually) must be encoded in imaging scheduling systems, with imaging results routed back to the oncology record. Restaging after recurrence must trigger re-biopsy (to assess for malignant transformation or acquired ALK resistance mutations) and re-evaluation of targeted therapy eligibility.

Key Monitoring Metrics

ALK and Fusion Gene Testing Completeness

Testing Completeness and Reflex Logic

  • ALK IHC ordered on all newly diagnosed IMT specimens at time of initial pathology report: order completeness (target: 100%)
  • ALK IHC-positive result reflexing automatically to ALK FISH or RNA fusion confirmation: reflex automation rate (target: 100%)
  • ALK IHC-negative IMT cases reflexing to comprehensive RNA fusion sequencing panel: reflex rate (target: > 90%)
  • Comprehensive RNA fusion panel result including ROS1, NTRK, RET, PDGFR-beta fusion assessment: panel completeness rate

Result Routing and CDS Triggers

  • ALK fusion result (IHC/FISH/RNA) routed to OIS structured biomarker field within 4 hours of sign-out: routing rate
  • ALK fusion generating crizotinib/alectinib/lorlatinib CDS alert in OIS for unresectable or recurrent disease: trigger rate (target: 100%)
  • ROS1 fusion generating entrectinib/crizotinib CDS alert: trigger rate (target: 100%)
  • NTRK1/2/3 fusion generating larotrectinib/entrectinib histology-agnostic TRK inhibitor CDS alert: trigger rate (target: 100%)
  • RET fusion generating selpercatinib/pralsetinib CDS alert: trigger rate
  • Any actionable fusion result generating clinical trial eligibility flag within 24 hours of OIS routing: trigger rate

Time Metrics

  • Time from IMT biopsy receipt to ALK IHC sign-out: target ≤ 5 business days
  • Time from ALK IHC sign-out to confirmatory ALK FISH or RNA fusion result: target ≤ 7 business days
  • Time from comprehensive RNA fusion panel order to final sign-out: target ≤ 10 business days

Targeted Therapy CDS and Adherence

CDS Acknowledgment

  • Actionable fusion CDS alert acknowledged by oncologist within 2 business days: acknowledgment rate (target: > 90%)
  • IMT targeted therapy prescription generated within 10 business days of unresectable or recurrent disease determination for ALK+ patients: prescribing timeliness (target: > 80%)
  • Prior authorization submission for crizotinib/alectinib/larotrectinib/entrectinib initiated within 5 business days of prescription: PA initiation rate

Treatment Adherence and Toxicity

  • Crizotinib or next-gen ALK inhibitor dispensed and patient counseled on vision, GI, and QTc side effects before first dose: pre-treatment counseling rate (target: 100%)
  • Monthly toxicity assessment (CTCAE grade) for ALK inhibitor patients: assessment completion rate (target: > 90%)
  • QTc prolongation screening (ECG) at baseline and after dose escalation for crizotinib: ECG compliance rate
  • Grade ≥ 3 hepatotoxicity (ALT/AST > 5x ULN) triggering drug hold CDS and hepatology consult: trigger rate (target: 100%)
  • Response assessment CT or MRI at 8–12 weeks after targeted therapy initiation: imaging compliance (target: > 85%)

Resistance and Escalation

  • Disease progression on crizotinib triggering re-biopsy order for ALK resistance mutation testing (G1202R, L1196M): trigger rate (target: > 90%)
  • ALK resistance mutation identified on re-biopsy generating next-generation ALK inhibitor CDS alert: trigger rate (target: 100%)
  • Progression on first-generation ALK inhibitor without re-biopsy: documentation of clinical rationale required

Rare Tumor Registry and Multi-Center Coordination

Registry Enrollment

  • Newly diagnosed IMT cases identified from pathology sign-out and enrolled in institutional rare tumor registry within 30 days: enrollment timeliness (target: > 85%)
  • Structured molecular data (fusion type, FISH result, RNA panel) transmitted to registry at time of enrollment: data completeness rate
  • Cases enrolled in cooperative group or national sarcoma registry when available: enrollment rate (target: > 70% for eligible pediatric patients)

Multi-Center Referral

  • Patients with unresectable or locally advanced IMT referred to high-volume sarcoma center within 15 business days of diagnosis: referral timeliness
  • Pathology material (H&E slides, block, molecular report) transmitted electronically to referral center within 5 business days of referral request: material transfer rate
  • Expert pathology review at high-volume center completed and returned to referring institution: review turnaround (target: ≤ 10 business days)

Pediatric and AYA Care Coordination

Fertility and Psychosocial Referrals

  • Fertility preservation consultation offered to all patients ≤ 40 years before initiation of cytotoxic therapy (if applicable): referral offer rate (target: 100%)
  • Psychosocial distress screening (NCCN distress thermometer or equivalent) completed at diagnosis and at 6 months: completion rate (target: > 85%)
  • Social work referral placed for patients with distress score ≥ 4 at any time point: cascade referral rate (target: 100%)

AYA Transition

  • Pediatric-to-AYA oncology care transition plan documented for patients turning 18 during active treatment: documentation rate (target: 100%)
  • AYA oncology consultation offered to patients aged 15–39 years at diagnosis: consultation offer rate

Recurrence Surveillance

Imaging Schedule Compliance

  • Surveillance CT or MRI of primary site at 3, 6, 12, 18, and 24 months post-resection: scheduling compliance (target: > 85%)
  • Annual surveillance imaging from year 3 to year 5 post-resection: scheduling compliance
  • Imaging results linked to oncology encounter within 5 business days of report sign-out: linkage rate

Recurrence Response

  • Local recurrence identified on surveillance imaging triggering MDT review within 10 business days: escalation rate (target: 100%)
  • Re-biopsy ordered for recurrent IMT to assess malignant transformation: order rate (target: > 85%)
  • Re-staging fusion testing (RNA panel) ordered for recurrent IMT in patients originally fusion-negative: retesting rate

Platform Setup

Observability Architecture for IMT Platforms

# Prometheus scrape config for IMT care platforms
scrape_configs:
  - job_name: alk_fusion_testing_router
    static_configs:
      - targets: ['molecular-router.internal:9090']
    scrape_interval: 30s

  - job_name: targeted_therapy_cds
    static_configs:
      - targets: ['targeted-therapy-cds.internal:9090']
    scrape_interval: 60s

  - job_name: rare_tumor_registry
    static_configs:
      - targets: ['rare-tumor-registry.internal:9090']
    scrape_interval: 300s

  - job_name: pediatric_aya_coordinator
    static_configs:
      - targets: ['aya-coordination.internal:9090']
    scrape_interval: 120s

  - job_name: recurrence_surveillance_scheduler
    static_configs:
      - targets: ['surveillance-sched.internal:9090']
    scrape_interval: 300s

ALK Fusion Routing Canary

# Pseudocode: ALK fusion routing canary for IMT
def run_alk_fusion_routing_canary():
    test_patient_id = "CANARY-IMT-ALK-001"
    inject_biomarker_result(
        patient_id=test_patient_id,
        test="ALK_RNA_FUSION",
        result={"fusion": "ALK-TPM3", "alk_ihc": "POSITIVE_3_PLUS"},
        tumor_type="IMT"
    )
    start = time.now()
    ois_field = poll_for_ois_field(
        patient_id=test_patient_id,
        field="alk_fusion_status",
        timeout=14400  # 4-hour SLA
    )
    latency = time.now() - start
    metrics.record("alk_fusion_routing_latency_seconds", latency)
    if ois_field is None:
        page_on_call("IMT canary: ALK fusion result not routed to OIS within 4-hour SLA")
    cds_alert = check_cds_alert(test_patient_id, alert_type="alk_inhibitor_eligible")
    if not cds_alert:
        alert_informatics_team("IMT canary: ALK inhibitor CDS alert not generated for ALK-fusion positive IMT")
    trial_flag = check_cds_alert(test_patient_id, alert_type="clinical_trial_eligible")
    if not trial_flag:
        alert_informatics_team("IMT canary: clinical trial eligibility flag not generated for IMT fusion case")

Targeted Therapy Toxicity Monitoring

# Pseudocode: monthly ALK inhibitor toxicity compliance check
ALK_INHIBITOR_TOXICITY_DOMAINS = [
    "hepatotoxicity_alt", "hepatotoxicity_ast", "qtc_prolongation",
    "vision_disturbance", "nausea", "edema", "neuropathy"
]

def check_alk_inhibitor_monthly_toxicity(patient_id, month_number):
    missing_labs = []
    for domain in ["hepatotoxicity_alt", "hepatotoxicity_ast", "qtc_prolongation"]:
        latest = get_lab_result(patient_id, domain, within_days=35)
        if latest is None:
            missing_labs.append(domain)
    if missing_labs:
        generate_cds_alert(
            patient_id=patient_id,
            alert_type="alk_inhibitor_monitoring_gap",
            message=f"Month {month_number}: missing safety labs: {', '.join(missing_labs)}"
        )
    alt_value = get_lab_result(patient_id, "hepatotoxicity_alt", within_days=7)
    uln = get_lab_reference_uln(patient_id, "ALT")
    if alt_value and uln and alt_value > 5 * uln:
        generate_cds_alert(
            patient_id=patient_id,
            alert_type="alk_inhibitor_hepatotoxicity_hold",
            severity="P1",
            message=f"ALT {alt_value:.0f} > 5x ULN — ALK inhibitor hold and hepatology consult required"
        )

Rare Tumor Registry Enrollment Automation

-- Auto-enroll newly diagnosed IMT in rare tumor registry
CREATE OR REPLACE PROCEDURE enroll_imt_in_registry(patient_id UUID, diagnosis_date DATE)
AS $$
BEGIN
  -- Check if already enrolled
  IF NOT EXISTS (
    SELECT 1 FROM rare_tumor_registry_enrollments
    WHERE patient_id = patient_id AND tumor_type = 'IMT'
  ) THEN
    INSERT INTO rare_tumor_registry_enrollments
      (patient_id, tumor_type, diagnosis_date, enrollment_date, status, created_at)
    VALUES
      (patient_id, 'IMT', diagnosis_date, CURRENT_DATE, 'PENDING_CONSENT', NOW());

    INSERT INTO clinical_alerts (patient_id, alert_type, severity, message, created_at)
    VALUES (patient_id, 'RARE_TUMOR_REGISTRY_ENROLLMENT', 'P3',
            'IMT diagnosed — rare tumor registry enrollment consent to be obtained within 30 days', NOW());
  END IF;
END;
$$ LANGUAGE plpgsql;

Alerting Strategies

Severity Tiering

P1 — Immediate Clinical Impact

  • ALK/fusion gene molecular routing engine down; targetable fusion results not reaching OIS or CDS
  • Targeted therapy irAE monitoring offline; grade ≥ 3 hepatotoxicity not generating drug hold alerts for ALK inhibitor patients
  • Recurrence surveillance imaging result routing failure; new lesion reports not reaching oncology record
  • Multi-center referral material transfer system offline; pathology and imaging not transmitting to sarcoma referral center

P2 — Degraded Operation

  • ALK fusion result routing latency > 8 hours from sign-out
  • Targeted therapy monthly toxicity lab compliance < 80% for active ALK/ROS1/NTRK inhibitor patients
  • Registry enrollment rate < 70% for newly diagnosed IMT cases: enrollment workflow audit
  • Recurrence surveillance imaging scheduling compliance < 75% at 6-month time point

P3 — Quality and Compliance

  • ALK IHC reflex to confirmatory testing automation failure > 5%: LIS reflex logic audit
  • Clinical trial eligibility flag generation rate < 85% for actionable fusion-positive IMT: CDS configuration review
  • AYA transition plan documentation rate < 80% for patients turning 18 during treatment

On-Call Escalation

  • Clinical informatics engineer (primary for P1 routing and platform failures)
  • Oncology pharmacist on call (ALK inhibitor hepatotoxicity hold and dose-reduction decisions out of hours)
  • Sarcoma program coordinator (multi-center referral material transfer failures and registry escalations)

Notification Channels

  • P1: PagerDuty page + SMS to primary and secondary on-call
  • P2: Slack #imt-sarcoma-informatics + email to sarcoma oncology informatics lead
  • P3: Automated JIRA ticket to oncology informatics backlog; monthly registry enrollment and fusion testing compliance report to sarcoma MDT coordinator

Conclusion

Inflammatory myofibroblastic tumor exemplifies the precision oncology paradigm applied to a rare, biologically heterogeneous, and predominantly young patient population. The availability of multiple approved and trial-stage targeted therapies — crizotinib, alectinib, lorlatinib for ALK fusions; entrectinib and larotrectinib for ROS1 and NTRK fusions; selpercatinib for RET fusions — transforms IMT from an unresectable disease with limited systemic options into a targetable condition where biomarker routing quality directly determines treatment access.

Engineering teams supporting IMT programs should prioritize comprehensive RNA fusion panel reflex automation, multi-kinase CDS alert coverage, and rare tumor registry enrollment pipelines. Given the pediatric and AYA population, platforms must also support fertility, psychosocial, and transition care workflows that are often absent in adult oncology informatics stacks. With observability infrastructure calibrated to IMT's molecular complexity and multi-center care model, digital health platforms become an essential enabler of equitable, guideline-concordant care for one of oncology's most biomarker-rich rare tumors in 2026.

Monitor your app with Vigilmon

Free plan — 5 monitors, no credit card required. Up and running in 60 seconds.

Start free →
← Back to all articles